Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096675 Target Snapshot

Integrin alpha-V/beta-5 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
493Compounds
74Assays
0Approved Drugs
620.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Integrin alpha-V/beta-5 shows late clinical disease relevance led by adult glioblastoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P06756. Start with adult glioblastoma, then reuse UniProt P06756 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with adult glioblastoma, then reuse UniProt P06756 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
adult glioblastoma

Integrin alpha-V/beta-5 shows late clinical disease relevance led by adult glioblastoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with adult glioblastoma because it currently carries late clinical support. Linked drugs include CILENGITIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Integrin alpha-V/beta-5 as ChEMBL target CHEMBL2096675, mapped to UniProt P06756. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Integrin alpha-V/beta-5
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2096675
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P06756
Integrin alpha-V
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Integrin alpha-V/beta-5 is the right protein anchor across sources, using UniProt P06756 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why adult glioblastoma is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntegrin alpha-V/beta-5
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP06756
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntegrin alpha-V
UniProt AccessionP06756
Component TypeProtein
Sequence Length1048 aa

Integrin alpha-V

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Integrin alpha-V/beta-5, mapped to UniProt P06756. ChEMBL maps the protein component as Integrin alpha-V. Sequence length is 1048 aa.

Mapped IDP06756
Review nameIntegrin alpha-V/beta-5
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Integrin alpha-V/beta-5 shows late clinical disease relevance led by adult glioblastoma. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
adult glioblastoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCILENGITIDE
Late clinical Phase III
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugCILENGITIDE
Clinical signal Phase II
melanoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugCILENGITIDE
Linked drugINTETUMUMAB
Clinical signal Phase II
prostate cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugABITUZUMAB
Linked drugCILENGITIDE
Clinical signal Phase II
anaplastic astrocytoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCILENGITIDE
Clinical signal Phase II
anaplastic oligodendroglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugCILENGITIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with adult glioblastoma because it currently carries late clinical support. Linked drugs include CILENGITIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseadult glioblastoma
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
5
Phase I
Assay Mix

Activity Type Distribution

IC50597.0
KI5.0
EC5016.0
KD2.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL109930 10.0 IC50 0.1 Preclinical
CHEMBL5889173 10.0 IC50 0.1 Preclinical
CHEMBL5914164 10.0 IC50 0.1 Preclinical
CHEMBL5951981 10.0 IC50 0.1 Preclinical
CHEMBL411941 9.96 IC50 0.11 Preclinical
CHEMBL429876 9.89 IC50 0.13 Clinical
CHEMBL590547 9.77 IC50 0.17 Preclinical
CHEMBL327102 9.7 IC50 0.2 Preclinical
CHEMBL5781301 9.7 IC50 0.2 Preclinical
CHEMBL5802710 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

55
5.0
44
5.5
38
6.0
50
6.5
71
7.0
56
7.5
57
8.0
49
8.5
42
9.0
25
9.5
pChEMBL
Assay Landscape

Assay Landscape

74
Total Assays
447
Tested Compounds
2
Assay Types
Binding — 72 assays, 447 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 45 262 7.3
cell-based format 24 175 7.2
assay format 2 5 8.3
tissue-based format 1 5 7.6
Functional — 2 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 14 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine